Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exicure Inc XCUR

Healthcare Biotechnology
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is into exploring strategic alternatives to maximize stockholder value. It is engaging in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see... see more

Recent & Breaking News (NDAQ:XCUR)

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Business Wire December 26, 2024

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Business Wire December 20, 2024

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Business Wire November 14, 2024

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Business Wire September 18, 2024

Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

Business Wire September 9, 2024

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Business Wire August 26, 2024

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Business Wire August 19, 2024

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Business Wire August 15, 2024

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Business Wire August 13, 2024

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Business Wire August 8, 2024

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Business Wire August 1, 2024

Exicure, Inc. Reports First Quarter 2024 Financial Results

Business Wire June 17, 2024

Exicure, Inc. Reports Full Year 2023 Financial Results

Business Wire June 6, 2024

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Business Wire May 23, 2024

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Business Wire May 16, 2024

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Business Wire April 22, 2024

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Business Wire February 5, 2024

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Business Wire November 28, 2023

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Business Wire August 23, 2023

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Business Wire August 11, 2023